carmustine has been researched along with Fibrosarcoma in 17 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Fibrosarcoma: A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| ") was administered just prior to an alkylating agent, the combination treatment produced significantly more tumor cell killing across the dosage range of each alkylating agent tested compared with the alkylating agent alone." | 5.28 | Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma. ( Bubley, G; Coleman, CN; Eder, JP; Frei, E; Herman, TS; Holden, SA; Tanaka, J; Teicher, BA, 1991) |
| "To examine the ability of SR-4233, a new cytotoxic agent, to overcome the resistance of hypoxic tumor cells to antitumor alkylating agents, we tested the cytotoxic effect of SR-4233 alone and in combination with varying doses of cisplatin (CDDP), cyclophosphamide (CPM), carmustine (BCNU), or melphalan (L-PAM) on tumor cells and bone marrow cells isolated from C3H/FeJ mice bearing the FSaIIC fibrosarcoma." | 3.68 | Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma. ( Ara, G; Coleman, CN; Herman, TS; Holden, SA; Teicher, BA, 1992) |
| " Using a new concentrated perfluorochemical emulsion, a wide range of perfluorochemical doses has been examined in combination with melphalan, cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in the FSaIIC fibrosarcoma." | 3.68 | A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents. ( Ara, G; Ha, CS; Herman, TS; Holden, SA; Northey, D; Teicher, BA, 1992) |
| ") was administered just prior to an alkylating agent, the combination treatment produced significantly more tumor cell killing across the dosage range of each alkylating agent tested compared with the alkylating agent alone." | 1.28 | Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma. ( Bubley, G; Coleman, CN; Eder, JP; Frei, E; Herman, TS; Holden, SA; Tanaka, J; Teicher, BA, 1991) |
| "Treatment with lonidamine increased the cytotoxicity of each drug by 1." | 1.28 | Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. ( Epelbaum, R; Frei, E; Herman, TS; Holden, SA; Liu, SD; Teicher, BA, 1991) |
| "Etoposide alone was essentially additive with the alkylating drugs for both tumor-cell and bone-marrow killing, except for BCNU, where a substantial increase in tumor-cell killing occurred (0." | 1.28 | Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo. ( Dezube, B; Frei, E; Herman, TS; Holden, SA; Tanaka, J; Teicher, BA, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (52.94) | 18.7374 |
| 1990's | 8 (47.06) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hahn, GM | 2 |
| Mulcahy, RT | 1 |
| Dembs, N | 1 |
| Tannock, IF | 1 |
| Teicher, BA | 11 |
| Holden, SA | 10 |
| Chen, YN | 1 |
| Ara, G | 3 |
| Korbut, TT | 1 |
| Northey, D | 2 |
| Herman, TS | 6 |
| Coleman, CN | 2 |
| Ha, CS | 1 |
| Ning, SC | 1 |
| Hopkins, RE | 1 |
| Menon, K | 1 |
| Tanaka, J | 2 |
| Eder, JP | 3 |
| Bubley, G | 1 |
| Frei, E | 4 |
| Epelbaum, R | 1 |
| Liu, SD | 1 |
| Dezube, B | 1 |
| Neilan, BA | 1 |
| Henle, KJ | 1 |
| Crawford, JM | 1 |
| Lin, Y | 1 |
| Cathcart, KN | 3 |
| Luchette, CA | 1 |
| Flatow, J | 1 |
| Schnipper, LE | 2 |
| Rose, CM | 1 |
| Wehrle, JP | 1 |
| Li, SJ | 1 |
| Rajan, SS | 1 |
| Steen, RG | 1 |
| Glickson, JD | 1 |
17 other studies available for carmustine and Fibrosarcoma
| Article | Year |
|---|---|
Does the mode of heat induction modify drug anti-tumour effects?
Topics: Animals; Bleomycin; Carmustine; Fibrosarcoma; Hindlimb; Hot Temperature; Mice; Mice, Inbred C3H; Neo | 1982 |
Time-dose relationships for simultaneous misonidazole and 1,3-bis(2-chloroethyl)-1-nitrosourea exposures in vitro.
Topics: Animals; Carmustine; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Fib | 1983 |
In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU.
Topics: Animals; Body Weight; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Fibrosarcoma; Leukocy | 1980 |
CAI: effects on cytotoxic therapies in vitro and in vivo.
Topics: Aminoimidazole Carboxamide; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 1994 |
Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Bone Marrow; Carmustine; Cisplatin; Cyclophospham | 1992 |
A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents.
Topics: Administration, Inhalation; Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protoco | 1992 |
Combination therapy: lonidamine, hyperthermia, and chemotherapy against the RIF-1 tumor in vivo.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carmustine; Combined Modality Therapy; Fibrosarcoma; Fluo | 1991 |
Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents.
Topics: Alkylating Agents; Animals; Carbon Dioxide; Carmustine; Cattle; Cisplatin; Cyclophosphamide; Drug Sy | 1992 |
Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carbon Diox | 1991 |
Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carboplatin; Carmustine; Drug Resistance; Drug Scr | 1991 |
Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B | 1991 |
In vivo response of murine RIF tumors to thermochemotherapy.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Fibrosa | 1989 |
Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide.
Topics: Amifostine; Animals; Carmustine; Cell Line; Cyclophosphamide; Drug Interactions; Fibrosarcoma; Gluta | 1988 |
Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; | 1989 |
Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Surviva | 1987 |
Effect of Fluosol-DA/O2 on tumor-cell and bone-marrow cytotoxicity of nitrosoureas in mice bearing FSA-II fibrosarcoma.
Topics: Animals; Bone Marrow; Carbon Dioxide; Carmustine; Cell Survival; Drug Combinations; Fibrosarcoma; Fl | 1986 |
31P and 1H NMR spectroscopy of tumors in vivo: untreated growth and response to chemotherapy.
Topics: Animals; Carmustine; Cyclophosphamide; Fibrosarcoma; Glioma; Hydrogen; Magnetic Resonance Spectrosco | 1987 |